Show simple item record

dc.contributor.authorPataia, Vanessa
dc.contributor.authorPapacleovoulou, Georgia
dc.contributor.authorNikolova, Vanya
dc.contributor.authorSamuelsson, Anne-Maj
dc.contributor.authorChambers, Stephanie
dc.contributor.authorJansen, Eugene
dc.contributor.authorTaylor, Paul D
dc.contributor.authorPoston, Lucilla
dc.contributor.authorWilliamson, Catherine
dc.date.accessioned20200413
dc.date.available2018-06-22T11:04:16Z
dc.date.issued2018-05-24
dc.identifier.citationPaternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment. 2018 Int J Obes (Lond)en
dc.identifier.issn1476-5497
dc.identifier.pmid29795465
dc.identifier.doi10.1038/s41366-018-0095-0
dc.identifier.urihttp://hdl.handle.net/10029/622005
dc.description.abstractObesity is a heterogeneous phenotype and risk associations to non-communicable diseases such as cardiovascular disease and type 2 diabetes are influenced by several factors. The paternal metabolic status at the time of conception influences offspring susceptibility to developing obesity and adiposity-associated cardiometabolic disease. Cholestatic liver diseases are characterized by raised circulating serum bile acid levels and dyslipidemia, and are commonly treated with ursodeoxycholic acid (UDCA). We hypothesized that paternal cholestasis alters offspring susceptibility to developing obesity and adiposity-associated cardiometabolic disease and that this may be modified by paternal UDCA treatment.
dc.language.isoenen
dc.titlePaternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment.en
dc.typeArticleen
dc.identifier.journalInt J Obesity 2-19; 43(2):319-30en
html.description.abstractObesity is a heterogeneous phenotype and risk associations to non-communicable diseases such as cardiovascular disease and type 2 diabetes are influenced by several factors. The paternal metabolic status at the time of conception influences offspring susceptibility to developing obesity and adiposity-associated cardiometabolic disease. Cholestatic liver diseases are characterized by raised circulating serum bile acid levels and dyslipidemia, and are commonly treated with ursodeoxycholic acid (UDCA). We hypothesized that paternal cholestasis alters offspring susceptibility to developing obesity and adiposity-associated cardiometabolic disease and that this may be modified by paternal UDCA treatment.


This item appears in the following Collection(s)

Show simple item record